ADAR1 Capital Management LLC Acquires 86,158 Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR)

ADAR1 Capital Management LLC increased its position in Voyager Therapeutics, Inc. (NASDAQ:VYGR) by 212.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 126,792 shares of the company’s stock after buying an additional 86,158 shares during the period. ADAR1 Capital Management LLC owned 0.23% of Voyager Therapeutics worth $719,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of VYGR. Picton Mahoney Asset Management increased its position in shares of Voyager Therapeutics by 71.1% during the 4th quarter. Picton Mahoney Asset Management now owns 5,883 shares of the company’s stock valued at $33,000 after purchasing an additional 2,444 shares during the last quarter. Intech Investment Management LLC bought a new stake in shares of Voyager Therapeutics during the third quarter valued at about $74,000. Virtu Financial LLC bought a new stake in Voyager Therapeutics during the 4th quarter worth approximately $100,000. SG Americas Securities LLC grew its position in shares of Voyager Therapeutics by 86.7% during the 4th quarter. SG Americas Securities LLC now owns 23,044 shares of the company’s stock valued at $131,000 after purchasing an additional 10,704 shares in the last quarter. Finally, Verition Fund Management LLC purchased a new stake in shares of Voyager Therapeutics in the third quarter worth $216,000. 48.03% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, CEO Alfred Sandrock sold 10,885 shares of the business’s stock in a transaction that occurred on Wednesday, April 2nd. The stock was sold at an average price of $3.43, for a total transaction of $37,335.55. Following the transaction, the chief executive officer now owns 430,931 shares of the company’s stock, valued at approximately $1,478,093.33. The trade was a 2.46 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In the last ninety days, insiders sold 15,163 shares of company stock worth $59,158. 4.53% of the stock is currently owned by insiders.

Voyager Therapeutics Stock Performance

NASDAQ VYGR opened at $3.09 on Monday. The business’s fifty day moving average is $4.30 and its 200 day moving average is $5.54. Voyager Therapeutics, Inc. has a fifty-two week low of $2.95 and a fifty-two week high of $9.55. The company has a market capitalization of $170.59 million, a PE ratio of 4.35 and a beta of 1.02.

Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings data on Tuesday, March 11th. The company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.24). The business had revenue of $4.39 million during the quarter, compared to analysts’ expectations of $16.58 million. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. During the same quarter in the previous year, the firm earned $1.25 earnings per share. On average, sell-side analysts forecast that Voyager Therapeutics, Inc. will post -0.91 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on VYGR shares. HC Wainwright reissued a “buy” rating and set a $30.00 price objective on shares of Voyager Therapeutics in a report on Thursday, March 13th. Canaccord Genuity Group reduced their price objective on Voyager Therapeutics from $14.00 to $12.00 and set a “buy” rating on the stock in a research note on Thursday, March 13th. StockNews.com lowered Voyager Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, December 13th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Voyager Therapeutics in a research report on Wednesday, March 12th. Finally, Wells Fargo & Company set a $10.00 target price on shares of Voyager Therapeutics and gave the company an “overweight” rating in a research note on Wednesday, March 12th. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Voyager Therapeutics currently has an average rating of “Buy” and an average target price of $13.97.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.